Recursion Pharmaceuticals (RXRX) Competitors $5.45 +0.08 (+1.49%) Closing price 04:00 PM EasternExtended Trading$5.48 +0.03 (+0.55%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RXRX vs. VRNA, BBIO, ELAN, GRFS, TLX, TGTX, NUVL, LEGN, LNTH, and AXSMShould you be buying Recursion Pharmaceuticals stock or one of its competitors? The main competitors of Recursion Pharmaceuticals include Verona Pharma (VRNA), BridgeBio Pharma (BBIO), Elanco Animal Health (ELAN), Grifols (GRFS), Telix Pharmaceuticals Limited American Depositary Shares (TLX), TG Therapeutics (TGTX), Nuvalent (NUVL), Legend Biotech (LEGN), Lantheus (LNTH), and Axsome Therapeutics (AXSM). These companies are all part of the "pharmaceutical products" industry. Recursion Pharmaceuticals vs. Verona Pharma BridgeBio Pharma Elanco Animal Health Grifols Telix Pharmaceuticals Limited American Depositary Shares TG Therapeutics Nuvalent Legend Biotech Lantheus Axsome Therapeutics Recursion Pharmaceuticals (NASDAQ:RXRX) and Verona Pharma (NASDAQ:VRNA) are both mid-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, institutional ownership, earnings, community ranking, media sentiment, dividends, valuation, analyst recommendations and profitability. Which has higher earnings and valuation, RXRX or VRNA? Verona Pharma has higher revenue and earnings than Recursion Pharmaceuticals. Verona Pharma is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRecursion Pharmaceuticals$59.82M37.04-$328.07M-$1.77-3.08Verona Pharma$118.54M59.36-$54.37M-$2.00-43.39 Do analysts rate RXRX or VRNA? Recursion Pharmaceuticals presently has a consensus target price of $7.60, suggesting a potential upside of 39.45%. Verona Pharma has a consensus target price of $82.13, suggesting a potential downside of 5.36%. Given Recursion Pharmaceuticals' higher possible upside, analysts plainly believe Recursion Pharmaceuticals is more favorable than Verona Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Recursion Pharmaceuticals 0 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33Verona Pharma 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11 Is RXRX or VRNA more profitable? Verona Pharma has a net margin of 0.00% compared to Recursion Pharmaceuticals' net margin of -579.52%. Recursion Pharmaceuticals' return on equity of -76.56% beat Verona Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Recursion Pharmaceuticals-579.52% -76.56% -55.68% Verona Pharma N/A -79.54%-43.49% Does the MarketBeat Community believe in RXRX or VRNA? Verona Pharma received 305 more outperform votes than Recursion Pharmaceuticals when rated by MarketBeat users. Likewise, 81.01% of users gave Verona Pharma an outperform vote while only 56.14% of users gave Recursion Pharmaceuticals an outperform vote. CompanyUnderperformOutperformRecursion PharmaceuticalsOutperform Votes3256.14% Underperform Votes2543.86% Verona PharmaOutperform Votes33781.01% Underperform Votes7918.99% Do insiders and institutionals have more ownership in RXRX or VRNA? 89.1% of Recursion Pharmaceuticals shares are owned by institutional investors. Comparatively, 85.9% of Verona Pharma shares are owned by institutional investors. 8.4% of Recursion Pharmaceuticals shares are owned by insiders. Comparatively, 4.8% of Verona Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the media prefer RXRX or VRNA? In the previous week, Recursion Pharmaceuticals had 11 more articles in the media than Verona Pharma. MarketBeat recorded 16 mentions for Recursion Pharmaceuticals and 5 mentions for Verona Pharma. Verona Pharma's average media sentiment score of 1.23 beat Recursion Pharmaceuticals' score of 0.69 indicating that Verona Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Recursion Pharmaceuticals 7 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Verona Pharma 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, RXRX or VRNA? Recursion Pharmaceuticals has a beta of 0.84, suggesting that its share price is 16% less volatile than the S&P 500. Comparatively, Verona Pharma has a beta of 0.21, suggesting that its share price is 79% less volatile than the S&P 500. SummaryVerona Pharma beats Recursion Pharmaceuticals on 11 of the 19 factors compared between the two stocks. Get Recursion Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RXRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RXRX vs. The Competition Export to ExcelMetricRecursion PharmaceuticalsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.22B$3.10B$5.57B$8.66BDividend YieldN/A1.59%5.27%4.19%P/E Ratio-3.5633.8227.2020.17Price / Sales37.04476.37412.92161.90Price / CashN/A168.6838.2534.64Price / Book2.753.497.114.72Net Income-$328.07M-$72.35M$3.23B$247.80M7 Day Performance24.15%10.49%4.61%3.36%1 Month Performance25.87%24.23%13.35%9.71%1 Year Performance-36.77%-15.55%31.75%14.41% Recursion Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RXRXRecursion Pharmaceuticals1.8012 of 5 stars$5.45+1.5%$7.60+39.4%-36.9%$2.22B$59.82M-3.56400Trending NewsHigh Trading VolumeVRNAVerona Pharma1.7771 of 5 stars$83.56+2.9%$82.13-1.7%+597.8%$6.77B$118.54M-43.4630BBIOBridgeBio Pharma4.5407 of 5 stars$35.05+2.3%$57.09+62.9%+44.3%$6.66B$127.42M-12.31400Analyst UpgradeELANElanco Animal Health0.9412 of 5 stars$13.41-0.2%$15.17+13.1%-23.4%$6.65B$4.43B33.499,800Positive NewsGRFSGrifols3.1359 of 5 stars$8.27-0.4%N/A+22.0%$5.68B$7.21B7.0626,300Positive NewsTLXTelix Pharmaceuticals Limited American Depositary SharesN/A$16.76-1.4%$22.00+31.3%N/A$5.66B$783.21M0.00N/APositive NewsTGTXTG Therapeutics3.1447 of 5 stars$35.36+0.7%$40.80+15.4%+151.4%$5.60B$386.39M-352.88290Analyst RevisionNUVLNuvalent2.4678 of 5 stars$76.39+2.4%$115.50+51.2%-3.9%$5.50BN/A-22.0940Positive NewsLEGNLegend Biotech3.3288 of 5 stars$29.05+0.3%$76.20+162.4%-23.7%$5.35B$728.30M-30.641,070Analyst RevisionLNTHLantheus4.5695 of 5 stars$77.29+2.3%$132.67+71.6%+4.2%$5.34B$1.54B12.85700AXSMAxsome Therapeutics4.845 of 5 stars$107.43+2.2%$172.14+60.2%+48.7%$5.29B$432.16M-17.94380Trending NewsAnalyst ForecastInsider TradeAnalyst Revision Related Companies and Tools Related Companies Verona Pharma Competitors BridgeBio Pharma Competitors Elanco Animal Health Competitors Grifols Competitors Telix Pharmaceuticals Limited American Depositary Shares Competitors TG Therapeutics Competitors Nuvalent Competitors Legend Biotech Competitors Lantheus Competitors Axsome Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RXRX) was last updated on 6/10/2025 by MarketBeat.com Staff From Our PartnersBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredTrump Nominates “Next Elon”Elon's Replacement? You've been told Elon Musk has been forced out of DC. But did you know his successor ha...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump’s Secret WeaponThe Trump-Elon War Could Trigger an Economic Collapse - Here's Your Only Safe Exit This isn't just a war of...American Alternative | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Recursion Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Recursion Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
